BAY 43-9006 IN COMBINATION WITH CETUXIMAB AND IRINOTECAN

BAY 43-9006 与西妥昔单抗和伊立替康组合

• 批准号: 7604649
• 负责人: Wells A. Messersmith
• 金额: --
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604649
• 关键词: BAY 43-9006; Biological; Cetuximab/Irinotecan; Clinical; Colorectal Cancer; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Patients; Phase; Research; Research Personnel; Resources; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A phase I/II clinical, pharmacological, and biological study of BAY 43-9006 in combination with cetuximab and irinotecan in patients with advanced colorectal cancer.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 BAY 43-9006 联合西妥昔单抗和伊立替康治疗晚期结直肠癌患者的 I/II 期临床、药理学和生物学研究。